Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Aug 31;3(2):e12.
doi: 10.4081/hr.2011.e12. Epub 2011 Sep 1.

Tricuspid regurgitant velocity elevation in a three-year old child with sickle cell anemia and recurrent acute chest syndromes reversed not by hydroxyurea but by bone marrow transplantation

Raffaella Colombatti  1 , Elena Varotto, Silvia Ricato, Daniel Nardo, Nicola Maschietto, Simone Teso, Marta Pillon, Chiara Messina, Ornella Milanesi, Laura Sainati
Affiliations
Case Reports

Tricuspid regurgitant velocity elevation in a three-year old child with sickle cell anemia and recurrent acute chest syndromes reversed not by hydroxyurea but by bone marrow transplantation

Raffaella Colombatti et al. Hematol Rep. .

Abstract

Elevated Tricuspid Regurgitant Velocity (TRV) has been related to higher mortality in adults and to hemolysis, lower oxygen saturation during 6-minute walk test and acute chest syndrome (ACS) in children with sickle cell disease (SCD). Hydroxyurea (HU) has reduced TRV value in children and adults. We describe a three year old HbSS child with recurrent ACS, hypoperfusion of the left lung, mild hemolysis and persistent TRV elevation. TRV did not normalize after HU, despite improvement in clinical conditions and in baseline laboratory parameters related to hemolysis and blood viscosity, but normalized after bone marrow transplantation (BMT). Our experience suggests that in young patients, TRV reduction can be a positive concomitant effect of BMT.

Keywords: hydroxyurea, bone marrow transplantation.; pulmonary hypertension; sickle-cell disease; tricuspid regurgitant jet velocity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: the authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Pulmonary perfusion scintigraphy before (A) and 1 year after BMT (B)
See this image and copyright information in PMC

References

    1. Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood and Cancer. 2006;47:907–13. - PubMed
    1. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886–95. - PubMed
    1. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica. 2009;94:340–7. - PMC - PubMed
    1. Colombatti R, Maschietto N, Varotto E, et al. Pulmonary hypertension in sickle cell disease children under 10 years of age. Br J Haematol. 2010;150:601–9. - PubMed
    1. Morris CR. Vascular risk assessment in patients with sickle cell disease. Haematologica. 2011;96:1–5. - PMC - PubMed

Publication types

LinkOut - more resources